Home » FDA Panel Recommends Folotyn, Wants New Romidepsin Study
FDA Panel Recommends Folotyn, Wants New Romidepsin Study
The Oncologic Drugs Advisory Committee has voted 10–4 to recommend approval of Allos Therapeutics’ Folotyn in patients with relapsed or refractory peripheral T-cell lymphoma. The panel found Folotyn (pralatrexate) has a response rate and duration of response likely to predict clinical benefit, although some panel members were unconvinced.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May